ADVERTISEMENT
Daily Expert News
No Result
View All Result
Sunday, February 5, 2023
  • Home
  • World
  • Economy
  • Business
  • Markets
  • Arts & Culture
  • Education & Career
  • India
  • Politics
  • Top Stories
Daily Expert News
  • Home
  • World
  • Economy
  • Business
  • Markets
  • Arts & Culture
  • Education & Career
  • India
  • Politics
  • Top Stories
No Result
View All Result
Daily Expert News
No Result
View All Result
  • Home
  • World
  • Economy
  • Business
  • Markets
  • Arts & Culture
  • Education & Career
  • India
  • Politics
  • Top Stories
Home Politics

FDA advisors recommend the agency approve Moderna’s highly anticipated Covid vaccine for young children.

by Nick Erickson
June 15, 2022
in Politics
124 9
0
FDA advisors recommend the agency approve Moderna's highly anticipated Covid vaccine for young children.
152
SHARES
1.9k
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT


External advisors to the Food and Drug Administration voted unanimously on Wednesday to recommend that the agency release Moderna’s coronavirus vaccine for very young children, a move likely to pave the way for emergency vaccine approval later this week.

Panelists would vote later Wednesday afternoon on whether or not to recommend approval of Pfizer-BioNTech’s triple injection for children under age 5. Moderna’s dual vaccine is for children 6 months to 5 years old. (Watch the meeting live here.)

The FDA has said the companies’ clinical trial data shows that each vaccine met the criteria for safety and effectiveness in the age group.

More than two years after the pandemic, no vaccine has been approved in the United States for children under the age of 5, an unmet need that has baffled many parents. The FDA and the Centers for Disease Control and Prevention could act by the end of this week.

The panel of advisors voted 21-0 to recommend approval of Moderna’s pediatric vaccine. “I know the death rate from Covid and young children may not be extremely high,” Dr. Jay Portnoy, professor of pediatrics at Children’s Mercy Hospital in Kansas City, Mo. But he said, “It’s absolutely terrifying for parents.”

Regulators and company officials spent much of the day discussing side effects caused by vaccines, the vast majority of which were mild and tolerated in children in clinical trials: irritability and crying, drowsiness, fatigue and loss of appetite. Smaller numbers of trial participants had fevers, most of which did not exceed severe levels.

In younger age groups, fevers can be more debilitating and require more urgent medical attention, a dynamic that puts significant pressure on manufacturers to calibrate dosage correctly. Pfizer chose a dose only one-tenth the adult dose given in three shots; the first two are administered three weeks apart, and the third comes at least eight weeks after the second. Moderna used a quarter of the strength of the adult dose, given in two shots, four weeks apart.

Some difficult questions remain. Perhaps most importantly, neither vaccine has been tested against subvariants circulating in the United States. The clinical trials were largely conducted when the Omicron variant prevailed. Two subvariants, BA.4 and BA.5, could become dominant within a month.

The need to protect these children from Covid is great, Dr. Peter Marks, the FDA’s chief vaccine regulator, said at the meeting. He added that hundreds of children had died from Covid, a percentage he says is “quite related” to pediatric deaths during a major flu wave in 2009 and 2010.

Both vaccines under consideration on Wednesday appear to be significantly less effective against symptomatic infection than the adult vaccines when they were introduced. The FDA attributes that Omicron is much more adept at evading the vaccines’ defenses against infection than the original version of the virus.

Given the declining protection seen in adult recipients and the rapid evolution of the virus, regulators have said that children who were to receive the vaccines from Pfizer and Moderna would most likely need a booster. That would mean that Pfizer’s vaccine, developed with German company BioNTech, could end up as four doses, while Moderna’s could be three.

Both the Pfizer-BioNTech and Moderna vaccines produced levels of neutralizing or virus-blocking antibodies in children similar to those seen in teens and young adults ages 16 to 25. Pfizer’s vaccine has been approved for children ages 5 to 15 since last year, and regulators said it helped prevent hospitalizations and deaths.

After two doses, Pfizer’s vaccine was only 28 percent effective at preventing symptomatic infection in children 6 months through 4 years of age. Pfizer has suggested that the vaccine was 80 percent effective after a third dose, but the finding was based on just 10 cases from a subset of the 1,678 study participants. The study protocol specified that vaccine efficacy assessments should be based on at least twice as many cases; the small number of cases on which the efficacy finding was based was a topic of consternation among committee members and regulators on Wednesday.

dr. Doran Fink, a senior federal vaccine regulator, called Pfizer’s efficacy data tentative. “We consider it inaccurate and potentially unstable,” he said. “Exactly what vaccine efficacy is after dose three needs further data.”

Moderna found that the vaccine was 51 percent effective in preventing symptomatic infection in children 6 months to 2 years old, and 37 percent effective in children 2 through 5. Those results seem consistent with those reported in studies of adults during the Omicron era, the FDA said. Still, immunization continues to provide strong protection against serious illnesses leading to hospitalization and death.

A panelist on Wednesday asked if there was evidence of how children who had recovered from the virus responded to the vaccine — a common question among parents.

A Moderna official said the company’s study showed that young children who received Omicron and were vaccinated had a higher degree of protection, a conclusion supported by external research.

Although Moderna’s efficacy data seemed slightly stronger than Pfizer’s, scientists strongly cautioned against such comparisons.

“These are different populations. The studies were conducted at different times. The results are reported in different ways, with different endpoints,” said Dr. Jesse L. Goodman, a former chief scientist for the FDA. “Scientifically, we don’t have a direct comparison.”

ADVERTISEMENT
Tags: advisorsagencyanticipatedapproveChildrenCovidDailyExpertNewsFDAhighlyModernasRecommendvaccineyoung

Get real time update about this post categories directly on your device, subscribe now.

Unsubscribe
ADVERTISEMENT

Related Posts

The most important Senate races to watch in 2024
Politics

The most important Senate races to watch in 2024

January 30, 2023
A colossal off-year election in Wisconsin
Politics

A colossal off-year election in Wisconsin

January 16, 2023
How far right are the 20 Republicans who voted against McCarthy?
Politics

How far right are the 20 Republicans who voted against McCarthy?

January 5, 2023
In the absence of a speaker, part of the government ceases to function
Politics

In the absence of a speaker, part of the government ceases to function

January 5, 2023
Biden promotes compromise at a time of Republican chaos in Washington
Politics

Biden promotes compromise at a time of Republican chaos in Washington

January 4, 2023
Trump, mommy as McCarthy fluttered, calls on Republicans to embrace him as speaker.
Politics

Trump, mommy as McCarthy fluttered, calls on Republicans to embrace him as speaker.

January 4, 2023
ADVERTISEMENT
  • Trending
  • Comments
  • Latest
This optical illusion has a revelation about your brain and eyes

This optical illusion has a revelation about your brain and eyes

June 6, 2022
NDTV Coronavirus

Viral video: Chinese woman pinned down, Covid test carried out by force

May 5, 2022
NDTV News

TGIF Mood: Video of Bear Cub Dancing in the Forest Melts 2.5 Million Hearts

June 3, 2022
Hundreds In Sarees At UK

Hundreds of sarees at Britain’s Royal Ascot Horse Race to help Indian weavers

June 16, 2022
The shock of chopping up a Chanel bag

The shock of chopping up a Chanel bag

1
NDTV News

Watch: Researchers Discover the World’s Largest Factory in Australia

1
Skyrocketing global fuel prices threaten livelihoods and social stability

Skyrocketing global fuel prices threaten livelihoods and social stability

1
No Guns, No Dragons: Her Video Games Capture Private Moments

No Guns, No Dragons: Her Video Games Capture Private Moments

1
Please Click on allow

“Long live the legends”: the reunion of Chris Gayle and MS Dhoni. See photos | Cricket news

February 5, 2023
Pak PM Accused Of Treason For Consulting Nawaz Sharif Over New Army Chief

Pakistan, IMF at odds with over 900 billion rupees fiscal gap: report

February 5, 2023
Yashraj Mukhate

Yashraj Mukhate’s Version Of ‘Jhoome Jo Pathaan’ Forces Vishal Dadlani To Offer Collaboration

February 5, 2023
Iran pardons or commutes 'large' number of prisoners, state media report | CNN

Iran pardons or commutes ‘large’ number of prisoners, state media report | DailyExpertNews

February 5, 2023
ADVERTISEMENT

Recent News

Please Click on allow

“Long live the legends”: the reunion of Chris Gayle and MS Dhoni. See photos | Cricket news

February 5, 2023
Pak PM Accused Of Treason For Consulting Nawaz Sharif Over New Army Chief

Pakistan, IMF at odds with over 900 billion rupees fiscal gap: report

February 5, 2023

Categories

  • Africa
  • Americas
  • art-design
  • Arts
  • Arts & Culture
  • Asia Pacific
  • Astrology News
  • books
  • Books News
  • Business
  • Cricket
  • Cryptocurrency
  • Dance
  • Dining and Wine
  • Economy
  • Education & Career
  • Entertainment
  • Europe
  • Fashion
  • Food
  • Football
  • Gadget
  • Gaming
  • Golf
  • Health
  • Hot News
  • India
  • Indians Abroad
  • Lifestyle
  • Markets
  • Middle East
  • Most Shared
  • Motorsport
  • Movie
  • Music
  • New York
  • Opinion
  • Politics
  • press release
  • Real Estate
  • Review
  • Science & Space
  • Sports
  • Sunday Book Review
  • Tax News
  • Technology
  • Television
  • Tennis
  • Theater
  • Top Movie Reviews
  • Top Stories
  • Travel
  • Uncategorized
  • Web Series
  • World

Site Navigation

  • Home
  • Advertisement
  • Contact Us
  • Privacy & Policy
  • Other Links

We bring you the Breaking News,Latest Stories,World News, Business News, Political News, Technology News, Science News, Entertainment News, Sports News, Opinion News and much more from all over the world

©Copyright DailyExpertNews 2022

No Result
View All Result
  • Contact Us
  • Home
  • Top Stories
  • World
  • Economy
  • Business
  • Opinion
  • Markets
  • India
  • Education & Career
  • Arts
  • Advertisement
  • Tax News
  • Markets

©Copyright DailyExpertNews 2022

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?